vasoactive-intestinal-peptide has been researched along with Lymphoma--Large-B-Cell--Diffuse* in 1 studies
1 other study(ies) available for vasoactive-intestinal-peptide and Lymphoma--Large-B-Cell--Diffuse
| Article | Year |
|---|---|
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.
Adoptive therapy with ex vivo-expanded genetically modified antigen-specific T cells can induce remissions in patients with relapsed/refractory cancer. The clinical success of this therapy depends upon efficient transduction and expansion of T cells ex vivo and their homing, persistence and cytotoxicity following reinfusion. Lower rates of ex vivo expansion and clinical response using anti-CD19 chimeric antigen receptor (CAR) T cells have been seen in heavily pretreated lymphoma patients compared with B-cell acute lymphoblastic leukemia patients and motivate the development of novel strategies to enhance ex vivo T cell expansion and their persistence in vivo. We demonstrate that inhibition of phosphatidylinositol 3-kinase δ (PI3Kδ) and antagonism of vasoactive intestinal peptide (VIP) signaling partially inhibits the terminal differentiation of T cells during anti-CD3/CD28 bead-mediated expansion (mean, 54.4% CD27 Topics: Adult; Aged; Animals; Cell Culture Techniques; Cellular Senescence; Class I Phosphatidylinositol 3-Kinases; Female; Heterografts; Humans; Immunotherapy, Adoptive; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Mice; Middle Aged; Neurotensin; Purines; Quinazolinones; Recombinant Fusion Proteins; T-Lymphocytes; Vasoactive Intestinal Peptide | 2018 |